Market Overview:
The global nanoparticle drug delivery systems market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for targeted and controlled drug delivery systems, rising prevalence of chronic diseases, and growing investments by pharmaceutical companies in R&D activities for the development of novel nanoparticle drug delivery systems. Based on type, the global nanoparticle drug delivery systems market is segmented into liposomes drugs and lipid nanoparticle drugs. Liposomes drugs are further classified into small unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs). Lipid nanoparticles are sub-segmented into solid lipid particles (SLPs), nanostructured lipid carriers (NLCs), micelles, and lipoproteins. Based on application, the global nanoparticle drug delivery systems market is segmented into hospital pharmacies, retail pharmacies, and other applications such as research institutes & universities and contract research organizations (CROs). Geographically, the global Nanoparticle Drug Delivery Systems Market is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa .
Product Definition:
A nanoparticle drug delivery system (NDDS) is a drug delivery system in which drugs are delivered to patients in the form of nanoparticles. NDDSs are important because they can improve the efficacy and safety of drugs by targeting them to specific tissues or organs.
Liposomes Drugs:
Liposomes are small vesicular structures composed of phospholipids and water. They are capable of transporting drugs as well as other compounds within the cell. Liposomes were first discovered in a research study published in 1980, which was conducted by Dr. Alfred Dunhill, a physician at the University of London Hospital (UKH).
Lipid Nanoparticle Drugs:
Nanoparticle drug delivery systems are being increasingly used to deliver drugs across the human body. Nanoparticles are small particles made of materials such as lipids, polymers, inorganic salts and organic compounds. These nanoparticles have a wide range of applications including therapeutic and diagnostic agents for cancer treatment & diagnosis, gene therapy products for the treatment of genetic diseases and cosmetics products for skin enhancement among others.
Application Insights:
The other application segment includes research applications. Other applications of nanoparticle drug delivery systems include cancer treatment, gene therapy, and phototherapy among others. The other segment accounted for a significant share in the global market in 2017 owing to increasing R&D activities pertaining to the application of NNADs for various therapeutic purposes such as cancer treatment and phototherapy.
Hospital was the largest revenue-generating segment due to high usage of liposomal drugs for fluid resuscitation and as anesthetic agents at hospitals globally. Furthermore, growing investments by governments across countries towards building advanced healthcare infrastructure is expected to boost product demand from hospital-based settings over the forecast period.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of nanoparticle drug delivery systems manufacturers and research institutes. The region is expected to maintain its dominance over the forecast period due to increasing R&D investments by pharmaceutical companies and rising adoption of advanced technologies for treatment options.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing healthcare spending, growing patient awareness levels, government initiatives for improving healthcare facilities, and demand for cost-effective therapeutics in emerging markets such as China & India. Increasing prevalence of chronic diseases such as cancer & diabetes will further boost revenue generation from Asia Pacific region during the forecast period.
Growth Factors:
- Increasing demand for targeted drug delivery systems: The growing prevalence of chronic diseases, such as cancer and diabetes, is increasing the demand for targeted drug delivery systems. Nanoparticle-based drug delivery systems can target specific cells and tissues, which helps to improve the efficacy of drugs and reduce their side effects.
- Growing investment in nanotechnology research: The increasing investment in nanotechnology research is helping to drive the growth of the nanoparticle drug delivery market. Governments and private organizations are investing in nanotechnology research to develop new applications for nanoparticles, including nanoparticle-based drug delivery systems.
- Rising number of clinical trials: A large number of clinical trials are being conducted on nanoparticle-based drug delivery systems to evaluate their safety and efficacy. This is helping to increase awareness about these systems among healthcare professionals and patients, which is driving their adoption worldwide.
- Technological advancements: The development of novel technologies that can be used for manufacturing nanoparticles is aiding the growth of this market segmentationally advanced methods that can produce more uniform particles with better functional properties are being developed constantly .This will help fuel future market growth as well 5) Emergence Of Nano Delivery Systems As Key Component In Drug Discovery And Development Processes - Driven By Factors Such As Increased Efficiency And Reduced Costs
Scope Of The Report
Report Attributes
Report Details
Report Title
Nanoparticle Drug Delivery Systems Market Research Report
By Type
Liposomes Drugs, Lipid Nanoparticle Drugs
By Application
Hospital, Retail Pharmacy, Other
By Companies
Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
148
Number of Tables & Figures
104
Customization Available
Yes, the report can be customized as per your need.
Global Nanoparticle Drug Delivery Systems Market Report Segments:
The global Nanoparticle Drug Delivery Systems market is segmented on the basis of:
Types
Liposomes Drugs, Lipid Nanoparticle Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Kinyond
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Ipsen
- Sayre Therapeutics
- Jazz
- Alnylam
- Bausch Health
- Acrotech Biopharma
- Takeda
- Chiesi Farmaceutici
- Gilead Sciences
Highlights of The Nanoparticle Drug Delivery Systems Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomes Drugs
- Lipid Nanoparticle Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nanoparticle Drug Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nanoparticle drug delivery systems are a type of medical device that uses nanoparticles to transport drugs and other therapeutic agents to specific locations in the body. Nanoparticles are small, but they can travel through the body more easily than larger particles. This makes them an attractive option for delivering drugs and other therapies to specific areas of the body. One potential advantage of using nanoparticles for drug delivery is that they can penetrate deep into tissues. This means that they may be able to reach areas where traditional medications don't have much impact. Additionally, nanoparticles may be more effective at crossing barriers in the blood-brain barrier, which could lead to better treatment outcomes for conditions like Alzheimer's disease or dementia
Some of the major players in the nanoparticle drug delivery systems market are Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences.
The nanoparticle drug delivery systems market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nanoparticle Drug Delivery Systems Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nanoparticle Drug Delivery Systems Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nanoparticle Drug Delivery Systems Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nanoparticle Drug Delivery Systems Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nanoparticle Drug Delivery Systems Market Size & Forecast, 2020-2028
4.5.1 Nanoparticle Drug Delivery Systems Market Size and Y-o-Y Growth
4.5.2 Nanoparticle Drug Delivery Systems Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Liposomes Drugs
5.2.2 Lipid Nanoparticle Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nanoparticle Drug Delivery Systems Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nanoparticle Drug Delivery Systems Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Liposomes Drugs
9.6.2 Lipid Nanoparticle Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Liposomes Drugs
10.6.2 Lipid Nanoparticle Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Liposomes Drugs
11.6.2 Lipid Nanoparticle Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Liposomes Drugs
12.6.2 Lipid Nanoparticle Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Liposomes Drugs
13.6.2 Lipid Nanoparticle Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nanoparticle Drug Delivery Systems Market: Competitive Dashboard
14.2 Global Nanoparticle Drug Delivery Systems Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Sun Pharmaceutical
14.3.3 CSPC
14.3.4 Kinyond
14.3.5 Teva
14.3.6 Fudan-Zhangjiang
14.3.7 Zydus Cadila
14.3.8 TTY Biopharma
14.3.9 Pacira
14.3.10 Luye Pharma
14.3.11 Leadiant Biosciences
14.3.12 Ipsen
14.3.13 Sayre Therapeutics
14.3.14 Jazz
14.3.15 Alnylam
14.3.16 Bausch Health
14.3.17 Acrotech Biopharma
14.3.18 Takeda
14.3.19 Chiesi Farmaceutici
14.3.20 Gilead Sciences
